Noninvasive Multimodality Imaging in ARVD/C  by te Riele, Anneline S.J.M. et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G VO L . 8 , N O . 5 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 5 . 0 2 . 0 0 7Noninvasive Multimodality Imaging
in ARVD/C
Anneline S.J.M. te Riele, MD,*y Harikrishna Tandri, MD,* Danita M. Sanborn, MD,z David A. Bluemke, MD, PHDxkABSTRACTFro
yD
Me
xD
Sci
ten
Dr
Pro
at
Fa
no
MaArrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a familial cardiomyopathy resulting in pro-
gressive right ventricular (RV) dysfunction and malignant ventricular arrhythmias. Although ARVD/C is generally
considered an inherited cardiomyopathy, the arrhythmogenic nature of the disease is striking. Affected individuals
typically present in the second to fourth decade of life with arrhythmias originating from the right ventricle. Over the past
decade, pathogenic ARVD/C-causing mutations have been identiﬁed in 5 genes encoding the cardiac desmosome.
Disruption of the desmosomal connection system between cardiomyocytes may be represented structurally by ventric-
ular enlargement, global or regional contraction abnormalities, RV aneurysms, or ﬁbrofatty replacement. These abnor-
malities are typically observed in predilection areas, including the subtricuspid region, basal RV free wall, and left
ventricular posterolateral wall. As such, structural and functional abnormalities on cardiac imaging constitute an
important diagnostic criterion for the disease. This paper discusses the current status and role of echocardiography,
cardiac magnetic resonance imaging, and computed tomography for suspected ARVD/C. (J Am Coll Cardiol Img
2015;8:597–611) © 2015 by the American College of Cardiology Foundation.A rrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inheritedcardiomyopathy characterized by ﬁbrofatty
replacement of the right ventricular (RV) myocar-
dium, predisposing patients to ventricular arrhyth-
mias and usually slowly progressive ventricular
dysfunction (1). The disease is inherited as an auto-
somal dominant trait with incomplete penetrance
and variable expressivity (2). Although the exact
prevalence of this condition is unknown, ARVD/C is
recognized as a major cause of sudden cardiac death
in the young and in athletes (3–5). Deﬁnite ARVD/C
diagnosis is on the basis of the presence of major and
minor criteria encompassing structural, histologic,
electrocardiographic, arrhythmic, and family history
criteria proposed by a Task Force in 2010 (Table 1)
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of the underlying pathophysiology, diagnostic im-
provements, and advanced therapeutic options.
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ABBR EV I A T I ON S
AND ACRONYMS
ARVD/C = arrhythmogenic
right ventricular dysplasia/
cardiomyopathy
CMR = cardiac magnetic
resonance
CT = computed tomography
EBCT = electron-beam
computed tomography
FAC = fractional area change
ICD = implantable
cardioverter-deﬁbrillator
LGE = late gadolinium
enhancement
LV = left ventricular
MDCT = multidetector
computed tomography
RV = right ventricular
TDI = tissue Doppler imaging
TFC = Task Force Criteria
3D = 3-dimensional
TTE = transthoracic
echocardiography
2D = 2-dimensional
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598replacement (13–15). Therefore, accurate
evaluation of ventricular structure and
function is essential for the evaluation of
patients and screening of their relatives. The
aim of this review is to provide a practical
and current approach to noninvasive imaging
for suspected ARVD/C.
IMAGING OF ARVD/C
ARVD/C may present a diagnostic challenge
for the physician. In our experience, over-
emphasis of imaging results without refer-
ence to other ARVD/C criteria may be
problematic. RV imaging abnormalities by
themselves are not the “gold standard” for
ARVD/C diagnosis. Rather, the diagnostic
Task Force Criteria (TFC) prescribe the use of
multiple diagnostic tests. In addition, many
imaging centers have little or no experience
with ARVD/C, and gaining experience is
difﬁcult because of the low prevalence of
disease. The clinical features and associated
structural ﬁndings of conditions included in
the differential diagnosis of ARVD/C aredescribed in Table 2. A more comprehensive descrip-
tion of ARVD/C mimics is available from Rastegar
et al. (16).
Many subjects with ARVD/C are young, and the
need for screening tools among genetically predis-
posed, but clinically asymptomatic individuals calls
for structural abnormalities to be identiﬁed prefer-
ably through noninvasive studies (17). For diagnostic
purposes, the 2010 TFC prescribe the use of trans-
thoracic echocardiography (TTE), cardiac magnetic
resonance (CMR), or RV angiography (6). Cardiac
computed tomography (CT) is not part of the diag-
nostic TFC. This reﬂected low use of cine CT for
ARVD/C because of high radiation dose and lack of
use of the technology in multicenter clinical trials.
However, a 2010 consensus document on the appro-
priate use of cardiac CT expressed the opinion that
CT could be used for ARVD/C evaluation using more
recently developed low radiation dose techniques
(18). In this review, we will focus on noninvasive
imaging modalities given their particular role in the
setting of ARVD/C.
The utility of imaging techniques for ARVD/C is
dependent on the technical aspects of the modality,
potential to visualize the right side of the heart,
experience of the technician, and expertise of the
interpreter. Recognition of the strengths and weak-
nesses of each technique is crucial to facilitate
optimal implementation of cardiac imaging inARVD/C evaluation (Table 3). TTE often is the ﬁrst-
line imaging modality in a patient with suspected
ARVD/C because of its widespread availability and
low cost. TTE provides structural and functional in-
formation on all cardiac chambers, although visuali-
zation of the RV requires special emphasis and
expertise. In addition, in patients with an implantable
cardioverter-deﬁbrillator (ICD), TTE may be used for
serial evaluation to evaluate disease progression.
CMR has high spatial resolution and a theoretically
unlimited ﬁeld of view, thereby allowing for detailed
visualization of RV wall motion abnormalities. In
addition, the 3-dimensional (3D) depiction of anat-
omy by CMR enables accurate measurement of RV
volumes and function. Moreover, CMR with late
gadolinium enhancement (LGE) offers the possibility
to visualize intramyocardial fat and ﬁbrosis, the
pathologic hallmarks of ARVD/C. Cardiac CT, in par-
ticular multidetector computed tomography (MDCT),
has excellent spatial resolution allowing for clear
delineation of the ventricular endocardium. In addi-
tion, quantitative evaluation of ventricular volumes
and function can be performed, and its capability to
depict fatty tissue makes it an interesting option in
the setting of ARVD/C. Until recently, the radiation
dose of cine CT was an important drawback. How-
ever, our experience has shown that radiation expo-
sure for cine CT may be reduced to clinically
appropriate values (1 to 2 mSv) while maintaining
good temporal and spatial resolution, reinforcing its
potential as a diagnostic tool in ARVD/C.
TRANSTHORACIC ECHOCARDIOGRAPHY
A TTE examination is an ideal screening tool to assess
RV size and function in patients with possible ARVD/
C. TTE can be performed and interpreted easily and at
low cost, and is widely accessible and portable. In
addition, the technique is particularly useful in
following affected individuals over time because of
the ability to perform serial imaging in patients who
have ICDs.
TTE FINDINGS. RV morphology. RV dilation is fre-
quently observed in patients with ARVD/C (19,20).
Data from the North American Multidisciplinary
Study showed that an enlarged RV outﬂow tract was
found in 100% of probands (19). In the 2010 TFC, a
major criterion for ARVD/C is fulﬁlled when there is
RV outﬂow tract dilation on the parasternal long-axis
($32 mm) or short-axis ($36 mm) view, along
with localized akinesia, dyskinesia, or aneurysms (6)
(Figures 1A and 1B). The presence of a wall motion
abnormality with only mild dilation ($29 to <32 mm
for parasternal long axis and $32 to <36 mm for
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599parasternal short axis) is a minor criterion (Table 1).
These cutoff values were on the basis of data of 69
probands from the North American Multidisciplinary
ARVD/C Study compared with 450 controls (6). It is
important to recognize that for both major and minor
criteria, a segmental wall motion abnormality also
needs to be present (regional akinesia or dyskinesia).
RV dilation is not speciﬁc to ARVD/C. It has
also been reported as a physiologic adaptation to
high-intensity exercise (21). In addition, RV enlarge-
ment in ARVD/C has been associated with an in-
creased risk of sudden death and ventricular
arrhythmias in athletes (4,22). Thus, the diagnosis of
ARVD/C in highly trained athletes is challenging.
A detailed medical and family history and careful
application of the TFC exclusive of RV structure and
function may help distinguish disease from normal
adaptation to high-intensity exercise. In the future,
the accuracy of TTE in this subset of individuals may
be improved by the use of newer TTE parameters,
such as tissue Doppler imaging (TDI) and spec-
kle tracking for RV myocardial strain and strain
rate (23).
In addition to RV enlargement, several morpho-
logic abnormalities have been noted on TTE in in-
dividuals with ARVD/C (Figure 2). These include
trabecular prominence and derangement and focal
aneurysms or sacculations. Although trabecular
hypertrophy/derangement has been described in pub-
lished reports with increased frequency in ARVD/C
(19), it is not speciﬁc to the disease, and thus is not part
of the imaging diagnostic criteria. Trabecular promi-
nence or derangement, assessed subjectively by the
core laboratory echocardiographers,was deﬁned in the
North American registry as thickened, hypertrophied
trabeculae that occupy a signiﬁcant amount of the RV
cavity at end diastole. It was themost frequently noted
morphologic abnormality in the North American
Multidisciplinary Study, observed in 54% of affected
individuals and not in any matched controls (19).
RV function. Because of the asymmetric geometry
of the RV and difﬁculty with visualization of the
entire RV endocardium from standard TTE views in
ARVD/C, estimation of RV volume and function by
conventional 2-dimensional (2D) TTE is challenging.
The RV fractional area change (FAC) from the apical
4-chamber view has been shown to be a useful
correlate of global RV function (24) and is decreased
in individuals with ARVD/C compared with controls
(19). In the 2010 TFC, the presence of severe RV
dysfunction (RV FAC #33%) combined with a local-
ized wall motion abnormality constitutes a major
diagnostic criterion, whereas mild RV dysfunction
(RV FAC >33% to #40%) constitutes a minor criterion(Figures 1C and 1D). Unfortunately, there have been no
large population studies describing normal values for
RV FAC normalized for sex or body size. For the 2010
TFC, the optimal cutoff points for FAC were deter-
mined using data from the Multidisciplinary Study
coupled with 450 controls. In the presence of regional
wall motion abnormality, an FAC #33% has a sensi-
tivity of 55% and a speciﬁcity of 95% for the diagnosis
of ARVD/C (6).
TTE PROTOCOL. TTE for ARVD/C evaluation should
be performed using current American Society of
Echocardiography guidelines (25). Because the RV
may be enlarged and therefore not completely visu-
alized on standard imaging planes, additional off-axis
images should be obtained to ensure that all parts of
the RV free wall are well visualized. This is especially
important given the patchy nature of this disease, to
not miss localized RV aneurysms.
NEWER ECHOCARDIOGRAPHIC TECHNIQUES IN ARVD/C.
Many new echocardiographic techniques have
emerged to complement a standard 2D TTE exami-
nation in the setting of ARVD/C. A simple Doppler
index of RV function, the RV myocardial performance
index, is independent of geometric assumptions (26)
and has been applied in diseases affecting the RV,
such as pulmonary hypertension (27). Preliminary
data regarding the utility of this index in ARVD/C
have demonstrated reduced RV myocardial perfor-
mance index in ARVD/C probands, even when global
RV function as assessed by FAC was normal (28).
Another group found this to be a less-informative
estimate of global RV dysfunction in ARVD/C (29).
This index needs to be tested in larger populations
to determine its diagnostic utility in individuals with
suspected ARVD/C.
Use of intravenous TTE contrast has been described
in populations with ARVD/C and can improve detec-
tion of subtle areas of regional dysfunction (30). Nemes
et al. (31) recently suggested that abnormalities of RV
perfusion can be detected in areas affected by
fatty inﬁltration. Larger populations of patients with
ARVD/C need to be studied to deﬁne the utility of
contrast TTE in this disease.
Tricuspid annular plane systolic excursion mea-
sured with M-mode echocardiography or Doppler
quantiﬁcation of tricuspid valve annular motion us-
ing TDI can be used to estimate global RV function
(20). These techniques are probably most useful when
RV dysfunction is global or in those with advanced
disease. Because annular motion may be preserved in
early or subtle forms of ARVD/C, the utility of the
tricuspid annular plane systolic excursion and TDI
systolic velocity in screening suspected cases or
TABLE 1 Revised 2010 TFC for ARVD/C*
1 Global or Regional Dysfunction and Structural Alterations
Major
2D echocardiographic criteria
Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following measured at end diastole:
- PLAX RVOT $32 mm (PLAX/BSA $19 mm/m2),
- PSAX RVOT $36 mm (PSAX/BSA $21 mm/m2), or
- FAC #33%
CMR criteria
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:
- RV EDV/BSA $110 ml/m2 (male) or $100 ml/m2 (female)
- RV ejection fraction #40%
RV angiography criteria
Regional RV akinesia, dyskinesia, or aneurysm
Minor
2D echocardiographic criteria
Regional RV akinesia or dyskinesia and 1 of the following measured at end diastole:
- PLAX RVOT $29 to <32 mm (PLAX/BSA $16–<19 mm/m2), or
- PSAX RVOT $32 to <36 mm (PSAX/BSA $18–<21 mm/m2), or
- FAC >33% #40%
CMR criteria
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:
- RV EDV/BSA $100–<110 ml/m2 (male) or $90–<100 ml/m2 (female)
- RV ejection fraction >40–#45%
2 Tissue Characterization of Wall
Major
Residual myocytes <60% by morphometric analysis (or <50% if estimated), with ﬁbrous replacement of the RV free wall myocardium
in $1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
Minor
Residual myocytes 60%–75% by morphometric analysis (or 50%–65% if estimated), with ﬁbrous replacement of the RV free wall
myocardium in $1 sample with or without fatty replacement of tissue on endomyocardial biopsy
3 Repolarization Abnormalities
Major
Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals >14 yrs of age (in the absence of complete RBBB)
Minor
Inverted T waves in V1 and V2 in individuals >14 yrs of age (in the absence of complete RBBB) or in V4, V5, and V6
Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 yrs of age in the presence of a complete RBBB
4 Depolarization/Conduction Abnormalities
Major
Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of T-wave) in the right precordial leads (V1–V3)
Minor
Late potentials by SAECG in $1 of 3 parameters in the absence of a QRSd of $110 ms on standard ECG:
- Filtered QRS duration ($114 ms)
- Duration of terminal QRS <40 mV $38 ms
- Root mean square voltage of terminal 40 ms #20 mV
Terminal activation duration of $55 ms measured from the nadir of the S-wave until the end of all depolarization deﬂections in the absence
of complete RBBB
Continued on the next page
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disease is limited.
3D TTE is an emerging tool that shows promise for
accurate estimation of RV volumes and RV ejection
fraction (32) (Figure 3, Online Video 1). Imaging of the
entire RV volume from a single transducer position
and single image acquisition is now possible using
3D TTE (33). RV volume calculated using this tech-
nique has been shown to have less variability thansimilar calculations by 2D TTE (34,35). RV ejection
fractions calculated by 3D TTE have been shown to be
decreased in ARVD/C compared with normal controls
(36,37). 3D TTE parameters also have been shown to
differentiate those with ARVD/C from unaffected
relatives; however, variability was higher than noted
in prior 3D TTE validation studies (32). At present,
there are limitations in image quality with 3D TTE, as
well as technical considerations of image acquisition,
TABLE 1 Continued
5 Arrhythmias
Major
Nonsustained or sustained VT of LBBB morphology with superior axis
Minor
Nonsustained or sustained VT of RVOT conﬁguration, LBBB morphology with inferior axis or with unknown axis
>500 PVCs per 24 h on Holter monitoring
6 Family History
Major
ARVD/C in ﬁrst-degree relative who meets current TFC
ARVD/C conﬁrmed pathologically at autopsy or surgery in a ﬁrst-degree relative
Identiﬁcation of a pathogenic mutation categorized as associated or probably associated with ARVD/C in the patient under evaluation
Minor
History of ARVD/C in ﬁrst-degree relative in whom it is not possible to determine whether the family member meets current TFC
Premature sudden death (<35 yrs of age) due to suspected ARVD/C in a ﬁrst-degree relative
ARVD/C conﬁrmed pathologically or by current TFC in second-degree relative
Major criteria count as 2 TFC points, and minor criteria count as 1 TFC point. Deﬁnite ARVD/C diagnosis is made with $4 TFC points, borderline ARVD/C diagnosis is made with
3 TFC points, and possible ARVD/C diagnosis is made with 2 TFC points. *Adapted from Marcus et al. (6).
ARVD/C ¼ arrhythmogenic right ventricular dysplasia/cardiomyopathy; BSA ¼ body surface area; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; EDV ¼ end-
diastolic volume; FAC ¼ fractional area change; LBBB ¼ left bundle branch block; PLAX ¼ parasternal long axis; PSAX ¼ parasternal short axis; PVC ¼ premature ventricular
complex; RBBB ¼ right bundle branch block; RV ¼ right ventricular; RVOT ¼ right ventricular outﬂow tract; SAECG ¼ signal-averaged electrocardiogram; TFC ¼ Task Force
Criteria; 2D ¼ 2-dimensional; VT ¼ ventricular tachycardia.
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601cropping, and measurement that require signiﬁcant
experience with the technique. Normal values and
disease cutpoints are still being established; thus, the
usefulness remains limited to specialized centers
with expertise in the use and limitations of 3D TTE.TABLE 2 Clinical Findings of Conditions Considered in the Differentia
Sarcoidosis Clinical ﬁndings: more common in women, African America
with extracardiac manifestations (often pulmonary/m
prolongation or high-grade atrioventricular block.
Useful imaging modalities: x-ray, CT, PET, CMR with LGE
Imaging ﬁndings: pulmonary granulomas, mediastinal lym
interventricular septum
Myocarditis Clinical ﬁndings: may present with a viral prodrome with
arrhythmias, complete heart block, or acute MI-like sy
Useful imaging modalities: echocardiography, CMR with L
Imaging ﬁndings: tissue edema (acute phase), concomitan
DCM Clinical ﬁndings: variable. May be familial. Ventricular arr
abnormalities.
Useful imaging modalities: echocardiography, CMR with L
Imaging ﬁndings: dilated LV with reduced function, midw
Athlete’s Heart Clinical ﬁndings: clinical history is indicative; subjects are t
show low heart rate, especially in young athletes.
Useful imaging modalities: echocardiography with deform
Imaging ﬁndings: balanced dilation of cardiac chambers, in
wall motion abnormalities, lack of LGE on CMR
Idiopathic RVOT
VT
Clinical ﬁndings: benign, nonfamilial condition, only 1 VT
Useful imaging modalities: echocardiography, CMR with L
Imaging ﬁndings: normal
Brugada
Syndrome
Clinical ﬁndings: ECG reveals RBBB and persistent ST-seg
Arrhythmias often occur in a sedentary setting (after
Useful imaging modalities: echocardiography, CMR with L
Imaging ﬁndings: normal
CT ¼ computed tomography; DCM ¼ dilated cardiomyopathy; LV ¼ left ventricular; LGE
tachycardia; other abbreviations as in Table 1.An important prerequisite of echocardiographic
fulﬁllment of TFC is the presence of a segmental wall
motion abnormality. However, it should be noted that
there is signiﬁcant variability in the morphology and
motion of the normal RV. As such, qualitativel Diagnosis of ARVD/C
ns, and Northern European (Scandinavian) whites. Usually nonfamilial disease pattern. May present
ediastinal lymphadenopathy, but any organ system may be involved). ECG may show PR-interval
phadenopathy, decreased LV function/heart failure, LGE (nonischemic pattern) in the
fever, myalgia, respiratory and gastrointestinal symptoms, new-onset atrial or ventricular
ndrome with chest pain, ST-T changes, and elevated cardiac enzymes
GE
t pericardial involvement, subepicardial patchy myocardial LGE (nonischemic pattern)
hythmias usually occur in the context of impaired LV systolic function and morphological
GE
all LGE in the septum
ypically engaged in intense and repetitive endurance type sports. Physical examination results may
ation imaging, CMR with LGE
creased ventricular wall thickness (<15 mm), absence of regional ventricular dysfunction or regional
morphology (LBBB with inferior axis), sinus rhythm ECG normal
GE
ment elevation in the right precordial leads (spontaneous or after provocative drug challenge).
a meal or at rest because of high vagal tone).
GE
¼ late gadolinium enhancement; MI ¼ myocardial infarction; PET ¼ positron emission tomography; VT ¼ ventricular
TABLE 3 Noninvasive Multimodality Imaging in ARVD/C
TTE CMR CT
Spatial resolution 0.5–1 mm* 1–2 mm 0.5 mm
Temporal resolution 15–60 ms 25–50 ms 50–100 ms
Availability þþ - þþ
Low cost þþ - -
Functional analysis þ þþ þ
Radiation dose None None Moderate for cine CT
(5–10 mSv)
Tissue characterization N/A þþ (fat/water/ﬁbrosis) þ (fat)
Remarks RV imaging requires special
emphasis/expertise; cardiac
devices are acceptable
Not inﬂuenced by habitus;
sensitive to arrhythmia;
generally not compatible
with cardiac devices
Sensitive to arrhythmia; cardiac
devices are acceptable
*Axial resolution.
N/A ¼ not available; TTE ¼ transthoracic echocardiography; other abbreviations as in Tables 1 and 2.
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602evaluation of RV wall motion abnormalities is sub-
jective and has been shown to have poor reproduc-
ibility (38). RV free wall myocardial velocity, strain,
and strain rate by echocardiographic deformationFIGURE 1 Quantitative Measures of RV Dilation and Function on Con
(A) RVOT measurement from the parasternal long-axis view. (B) RVOT
surements should be taken from the apical 4-chamber view at end dias
FAC¼ ([RV EDA – RV ESA]/RV EDA) $ 100). AoV¼ aortic valve; EDA¼ end
LA ¼ left atrium; LV ¼ left ventricle; RA ¼ right atrium; RV ¼ right ventric
echocardiography.imaging (by TDI or speckle tracking) are promising
tools to quantify global and regional ventricular
function. Systolic strain and systolic strain rate by TDI
have been shown to be reduced in patients withventional TTE
measurement from the parasternal short-axis view. RV FAC mea-
tole (C) and end systole (D). FAC is calculated from the formula:
-diastolic area; ESA¼ end-systolic area; FAC¼ fractional area change;
le; RVOT ¼ right ventricular outﬂow tract; TTE ¼ transthoracic
FIGURE 2 Morphologic Abnormalities in ARVD/C by TTE
(A) Apical 4-chamber view showing a highly trabeculated RV with trabecular derangement (arrows). (B) Subcostal long-axis view showing
localized RV free wall aneurysms (arrows). ARVD/C ¼ arrhythmogenic right ventricular dysplasia/cardiomyopathy; other abbreviations as in
Figure 1.
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603ARVD/C compared with healthy controls (37,38), and
use of this technique may be able to detect subtle
early abnormalities in asymptomatic mutation car-
riers (39). One limitation of TDI is angle dependence,FIGURE 3 Three-Dimensional Echocardiography in the Apical
View in a Patient With ARVD/C
Please note an enlarged globally hypokinetic RV. The apex is
signiﬁcantly dilated, and there is trabecular prominence
(arrows). The accompanying video ﬁle (Online Video 1) demon-
strates the severe global RV dysfunction with akinesia of the RV
apex and prominent trabeculae. Abbreviations as in Figures 1
and 2.a requirement that the motion of the wall that is
sampled is parallel to the ultrasound beam. As the RV
becomes signiﬁcantly enlarged in more advanced
ARVD/C, obtaining accurate and reproducible mea-
sures of RV peak systolic velocity, strain, and strain
rate can be challenging. It is possible that assessment
of RV strain and strain rate by speckle tracking might
be more applicable in the ARVD/C population because
it is not on the basis of Doppler and thus is not angle
dependent. Although the ﬁndings described in these
small research studies show promise, at present these
measures are best performed at specialized centers by
those experienced in the technique.
CMR IMAGING
CMR is well suited for comprehensive assessment
of the RV. It enables good assessment of cardiac
morphology and function while also allowing ﬂow
dynamic studies and tissue characterization. Impor-
tant advantages of CMR are the multiplane capability
andhigh spatial resolution,making it a highly sensitive
tool for detecting subtle contraction abnormalities.
CMR FINDINGS IN ARVD/C. The interaction of CMR
and ARVD/C began in 1987, when Casolo et al. (40)
demonstrated intramyocardial fat deposits using
conventional spin-echo imaging in a patient with
advanced ARVD/C. In 1989, Wolf et al. (41) described
“fat-like high signals” in the anterior RV and
RV outﬂow tract using spin-echo sequence in
7 subjects with ARVD/C. Subsequently, Blake et al. (42)
summarized prior CMR studies in a pictorial review
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604advocating that “the essence of the diagnosis depends
on the visualization of fat or extreme thinning in the
infundibulum and the inferior or diaphragmatic free
wall of the right ventricle.” Rather than ventricular
thinning, our current emphasis is on regional wall
motion abnormalities as the earlier and more reliable
abnormalities identiﬁed by CMR (Figure 4).
CMR ﬁndings associated with ARVD/C include
RV wall thinning, RV outﬂow tract enlargement,
trabecular disarray, ﬁbrofatty replacement, ventricu-
lar dilation, and global or regional systolic dysfunc-
tion (14,15,43). These abnormalities typically occur in
predilection sites including the RV base and LV lateral
wall (Central Illustration). Characteristic examples are
shown in Figures 4 to 6. Given that ﬁbrofatty change
is the pathological hallmark of ARVD/C, many im-
agers are inclined to look for it to help support the
diagnosis. In CMR studies, the prevalence of intra-
myocardial hyperintense signal on T1-weighted spin-
echo imaging indicative of fat ranged from 22% to
100% in different studies (44–48) (Figure 5). LGE CMR
indicative of ﬁbrosis was ﬁrst described by Tandri
et al. (49) in a cohort of 30 patients with ARVD/C. In
subsequent studies, RV LGE was observed in up to
88% of patients (49–51), and left ventricular (LV) LGE
was reported in up to 61% of cases (52,53) (Figure 6).
In our opinion, the presence of LGE represents a late
stage of ARVD/C; when LGE is present, multiple otherFIGURE 4 Four-Chamber Bright Blood Image by CMR of a
50-Year-Old Man With ARVD/C
Note the dilated RV with diastolic bulging in the subtricuspid
region (arrow). Please see Online Video 2. CMR ¼ cardiac
magnetic resonance; other abbreviations as in Figures 1 and 2.ﬁndings of advanced disease are typically present (RV
dilation and dysfunction).
Although the diagnostic Task Force recognized
the presence of fat and LGE in many patients with
ARVD/C, several limitations withheld their inclusion
in the TFC. Intramyocardial fat occurs physiologically
in older, obese patients and is not speciﬁc for ARVD/C
in the absence of functional abnormalities (54,55).
Intramyocardial fat was even observed in 85% of au-
topsy cases dying of noncardiac causes (56). In com-
parison with fat inﬁltration, the detection of LGE
indicative of ﬁbrosis has technological and clinical
limitations: Detection of ﬁbrosis in the RV is non-
speciﬁc and often hampered by the thin RV wall,
which may be even more pronounced in ARVD/C (44).
CMR PROTOCOL FOR ARVD/C. The CMR protocol
that we recommend for subjects with suspected
ARVD/C recently has been described by te Riele et al.
(15) (Table 4). In short, morphologic evaluation
is preferably performed on fast spin-echo or turbo
spin-echo imaging sequences. For cine imaging,
we recommend the use of electrocardiogram-gated,
steady-state free precession imaging at 1.5-T. Cine
images should be obtained in the short-axis and hori-
zontal long-axis views, whereas some sites prefer to
also acquire a vertical long-axis view of the RV. With
modern CMR scanners, the temporal resolution of cine
images is typically approximately 40 ms. Quantitative
analyses of the RV and LV are best performed on short-
axis images. A phase-selective inversion recovery
sequence is preferred for LGE imaging, because it is
less dependent on the precise inversion time (57).
ROLE OF CMR IN ARVD/C DIAGNOSIS. Given the
limitations of CMR evaluation of fat and ﬁbrosis in
ARVD/C, emphasis is currently placed on functional
abnormalities. In the 2010 TFC, CMR criteria rely on
the presence of both qualitative ﬁndings (RV regional
akinesia, dyskinesia, or dyssynchronous contraction)
and quantitative metrics (decreased RV ejection
fraction or increased indexed RV end-diastolic
volume) (Table 1). For derivation of quantitative cut-
off values, RV dimensions and function from 462
normal MESA (Multi-Ethnic Study of Atherosclerosis)
participants were compared with 44 probands in the
North American Multidisciplinary ARVD/C Study (6).
Cutoffs for major criteria (RV ejection fraction #40%
or indexed RV end-diastolic volume $110 ml/m2 for
men and $100 ml/m2 for women) were targeted to
achieve approximately 95% speciﬁcity. Minor criteria
(RV ejection fraction 40% to 45% or indexed RV end-
diastolic volume 100 to 110 ml/m2 for men and 90 to
100 ml/m2 for women) had good sensitivity (79% to
89%), but a consequently lower speciﬁcity (58). It is
CENTRAL ILLUSTRATION Traditional and Contemporary Model of Myocardial Involvement by ARVD/C
(Left) The concept of the “triangle of dysplasia” recognized primarily right ventricular (RV) disease involvement as visualized by angiography (RV base, outﬂow tract,
and apex). (Right) Contemporary 3-dimensional imaging and electroanatomic mapping frequently reveals biventricular involvement by ARVD/C, involving the RV base,
outﬂow tract, and lateral wall of the left ventricle. Two-dimensional angiography image in traditional ARVD/C model reproduced with kind permission from Springer
Science and Business Media (original manuscript Indik et al., Int J Cardiovasc Img 2012;28:995–1001).
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FIGURE 6 Phase-Sensitive Inversion Recovery Image After
Administration of a Gadolinium Chelate by CMR in a
47-Year-Old Woman With ARVD/C
There is delayed enhancement in the subtricuspid region, sug-
gestive of ﬁbrosis (arrow). Abbreviations as in Figures 2 and 4.
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606important to recognize that for both major and minor
criteria, a segmental wall motion abnormality also
needs to be present (regional akinesia, dyskinesia, or
dyssynchronous contraction).
A signiﬁcant problem in the interpretation of CMR
studies is the deﬁnition of normal versus subtle vari-
ants in RV contraction and morphology that may
represent early disease versus normal variation. Even
using quantitative parameters, there is considerable
inter-reader variation (10% to 15%) in determination of
RV volumes and ejection fraction. One approach may
be for CMR laboratories to assess their own normal
values in young adults and compare those values with
published normal values to calibrate readings. For
regional contraction abnormalities, no routine quan-
titative techniques are currently available.
ROLE OF CMR IN EARLY DIAGNOSIS AND RISK
STRATIFICATION. CMR has been extensively used
to characterize cardiac structural abnormalities in
ARVD/C. Many of these studies predated the 2010
TFC and were performed in tertiary centers without
the availability of genetic testing. As such, almost all
prior reports were populated by patients with severe
phenotypes, and only a few reports have reported on
structural changes in subjects with mild disease. A
recent study among 80 mutation carriers across the
spectrum of disease showed that wall motion abnor-
malities in the RV subtricuspid region were present
in 94% of subjects with CMR structural involvement
(13). Moreover, the RV subtricuspid region was ab-
normal in all patients with mild structural disease,FIGURE 5 Horizontal Long-Axis Dark Blood Image by CMR in
a 46-Year-Old Man With ARVD/C
Note the high-intensity signal suggestive of fat in the RV free
wall extending as “ﬁngers” into the myocardium (arrows). Also
note subepicardial fat and myocardial wall thinning in the LV
posterolateral wall (arrowhead). Abbreviations as in Figures 1, 2,
and 4.suggesting that abnormalities in this region may be
highly sensitive for early structural changes (Online
Video 2). Rastegar et al. (59) extended these ﬁndings
by demonstrating that fatty inﬁltration of the LV
posterolateral wall can be observed in a substantial
number of ARVD/C mutation carriers. In their study,
this ﬁnding had no association with age or degree of
RV structural abnormalities, challenging the concept
that LV abnormalities occur only in late stages of
ARVD/C.
An important, yet fairly new role of CMR lies in
risk stratiﬁcation for arrhythmic events. Previous
studies have shown that severe RV dysfunction and
LV involvement predict adverse outcome in ARVD/C
(60,61). A recently published study among 69
ARVD/C mutation carriers showed that sustained
arrhythmias during follow-up coincide with struc-
tural abnormalities on CMR (17). Moreover, no events
were observed among subjects with a normal CMR
evaluation during 6 years of follow-up. In addition,
Deac et al. (62) demonstrated that CMR was an
independent predictor of ventricular arrhythmia
among 369 consecutive patients undergoing evalua-
tion for ARVD/C. Large-scale studies from collabora-
tive international registries are necessary to further
enhance our understanding of arrhythmic risk strat-
iﬁcation in ARVD/C.
NOVEL ADVANCES IN ARVD/C EVALUATION BY CMR. An
important prerequisite of CMR fulﬁllment of TFC is
the presence of regional wall motion abnormality. As
such, fulﬁllment of CMR TFC is still “in the eye of
the beholder” (58). Although a regional wall motion
TABLE 4 Recommended CMR Protocol for ARVD/C Evaluation*
Sequence Imaging Plane Parameters Comments
Double-inversion recovery TSE/FSE
a) Axial: with and without fat
suppression
b) Short axis: without fat
suppression
a) Axial: obtain w6–8 images
centered on the LV/RV
b) Short axis: obtain w6–8
images centered on the LV
TR ¼ 2 R-R intervals, TE ¼ 5 ms (minimum-full)
(GE Healthcare, Fairﬁeld, Connecticut), TE
30 ms (Siemens, Munich, Germany), slice
thickness ¼ 5 mm, interslice gap ¼ 5 mm,
and FOV ¼ 28–34 cm
ETL 16–24
This sequence provides optimal tissue
characterization of the RV free wall.
Prescribe from the pulmonary artery to
the diaphragm. Fat suppression
improves reader conﬁdence in diagnosis
of RV fat inﬁltration.
SSFP bright blood cine images Stack of axial images or stack of
4-chamber cine images covering
the entire LV and RV.
Short axis. RV 3 chamber (optional)
TR/TE minimum, ﬂip angle ¼ 45–70, slice
thickness ¼ 8 mm, interslice gap ¼ 2 mm
FOV ¼ 36–40 cm, 16–20 views per segment.
Parallel imaging n ¼ 2 is desirable.
Axial and/or 4-chamber cine images are
best to assess RV wall motion. The
choice of axial versus 4-chamber view
depends on the experience of the
observer.
RV quantitative analysis is performed on
the short-axis cine images.
Gadolinium Is Administered According to Institutional Protocol (Usually 0.15–0.2 mmol/kg)
TI scout 4 chamber TI scout sequences or trial TI times to
suppress normal myocardium for
the right inversion time
Delayed gadolinium imaging
(phase-sensitive inversion
recovery recommended)
Axial, short axis, 4 chamber,
and vertical long axis
TR/TE per manufacturer recommendations ﬂip
angle ¼ 20–25, slice thickness ¼ 8 mm,
interslice gap ¼ 2 mm, FOV ¼ 36–40 cm,
no parallel imaging
Use phase-sensitive inversion recovery if available
PSIR is more robust and independent of
TI time. Optimal for imaging ﬁbrosis.
LV epicardial enhancement in the
inferolateral wall has been reported in
classic ARVD/C and in left dominant
forms.
*Reprinted with permission from te Riele et al. (15) (original publisher BioMed Central).
ETL ¼ echo train length; FOV ¼ ﬁeld of view; FSE ¼ fast spin echo; PSIR ¼ phase-sensitive inversion recovery; SSFP ¼ steady-state free precession; TE ¼ echo time; TI ¼ inversion time; TR ¼ repetition
time; TSE ¼ turbo spin echo; other abbreviations as in Tables 1 and 2.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 5 , 2 0 1 5 te Riele et al.
M A Y 2 0 1 5 : 5 9 7 – 6 1 1 Multimodality Imaging in ARVD/C
607abnormality is necessary for ARVD/C TFC fulﬁllment,
the normal RV has a nonuniform appearance, and
distinguishing normal from abnormal may be a chal-
lenge particularly in the setting of RV volume over-
load or prominent tethering of the RV free wall by
the moderator band. CMR tissue tracking, which has
been used to quantify regional ventricular function
in ARVD/C (63,64), may suggest one solution. We
recently presented data on 106 subjects (39 with overt
ARVD/C [genotypeþ, phenotypeþ], 37 with pre-
clinical ARVD/C [genotypeþ, phenotype], and 30
controls [genotype, phenotype]) who underwent
CMR tissue tracking using steady-state free preces-
sion imaging (64). Mean segmental strain decreased
in magnitude from control (37.7  11.2%) to pre-
clinical (32.2  11.5%) to overt ARVD/C (22.2 
11.9%), which constituted a highly signiﬁcant trend.
Differences between groups were most pronounced
in the subtricuspid region, and peak strain in the
4-chamber plane was shown to be a better
discriminator than peak strain in the axial plane,
likely due to through-plane motion in the axial
images. This approach will require improved stan-
dardization before routine use for ARVD/C is
advocated.
LGE depends on differences in signal intensity
between regions of scarring and adjacent normal
myocardium. In subjects with diffuse ﬁbrosis, thesedifferences in signal intensity are lacking, thus
resulting in false-negative results. Over the last
decade, measurement of myocardial T1 relaxation
times (T1 mapping) with gadolinium-enhanced in-
version recovery sequences has emerged as a novel
approach for quantiﬁcation of myocardial ﬁbrosis
(65). To the best of our knowledge, there have been
no reports on T1 mapping in ARVD/C in published
reports. A challenge of T1 mapping is that the tech-
nique has low spatial resolution, thus limiting appli-
cation to the LV rather than the RV. New research
pulse sequences have been developed to substan-
tially improve spatial resolution. This suggests the fu-
ture prospect of quantitative T1 mapping in ARVD/C.
Although the technique is still in development, the
strengths of T1 mapping as a noninvasive method
for direct quantiﬁcation of myocardial ﬁbrosis have
the potential to play an important role in ARVD/C
evaluation and management.
COMPUTED TOMOGRAPHY
Similar to CMR, CT allows for tissue characterization,
especially detection of fatty tissue, of the myocardium
(Figure 7). Newer-generation CT scanners, including
MDCT, provide superior spatial resolution compared
with CMR, with comparable or superior temporal
resolution. Quantitative evaluation of ventricular
FIGURE 7 Identiﬁcation of Fatty Tissue Using CT With Inverted Gray Scale in a 43-Year-Old Man With ARVD/C
(A) Short-axis and (B) horizontal long-axis CT images revealing hyperintense signal indicative of fat in the LV posterolateral wall (arrows). (C)
Reconstructed 3D image showing subepicardial fat in the LV posterolateral wall in the same patient (arrow). CT ¼ computed tomography; 3D ¼
3-dimensional; other abbreviations as in Figures 1 and 2.
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608mass and RV and LV volume and function using
MDCT has been validated against echocardiography
(66) and CMR (67). In addition, the widespread
availability of CT, reliable image quality, and fast
acquisition at low costs make CT popular for cardio-
vascular evaluation.
CT FINDINGS IN ARVD/C. Dery et al. (68) were the
ﬁrst to describe a dilated hypokinetic RV with wall
thinning by cine CT in a patient with ARVD/C in 1986.
Two years later, Villa et al. (69) reported on RV
enlargement, thinning of the RV myocardium, RV
subepicardial fat, and RV hypokinesia in 7 patients
with ARVD/C who underwent conventional CT. Bi-
opsy conﬁrmation of CT ﬁndings was provided by
Sotozono et al. (70) in 1990, who also showed excel-
lent biventricular anatomic visualization in an
advanced ARVD/C case.
Kimura et al. (71) illustrated the utility of helical
CT in ARVD/C evaluation by revealing abnormal RV
structure and function among 32 patients who un-
derwent single-row detector helical CT. Compared
with conventional CT, electron-beam computed to-
mography (EBCT) received considerable attention
because of its excellent temporal resolution with
motionless cardiac and cross-sectional imaging. The
use of EBCT in ARVD/C was ﬁrst published in 1993.
At that time, Hamada et al. (72) described an
“enlarged RV, scalloped surface of the free wall,
conspicuous trabeculations with low attenuation,
and abundant epicardial adipose tissue” in 4patients. The same study revealed regional dys-
function and depressed RV regional dysfunction on
quantitative evaluation. Subsequently, Tada et al.
(73) showed that EBCT ﬁndings have a high corre-
lation with abnormalities on electrophysiologic
study. The frequencies of epicardial fat, scalloping,
low-attenuation trabeculae, and intramyocardial
fat in this study were 86%, 79%, 71%, and 50%,
respectively.
Although EBCT scanners are no longer generally
available, similar cine and morphologic ﬁndings can
be visualized using MDCT scanners. The relatively
low spatial resolution and low signal-to-noise ratio of
EBCT limited accurate morphological assessment
(74). MDCT allows for improved visualization of the
myocardium with excellent spatial resolution and
high signal-to-noise ratio, and thus could be more
suitable for the assessment of biventricular tissue
involvement (74). Before the ﬁrst comprehensive
study of MDCT in ARVD/C was performed (75), pub-
lished data on MDCT in ARVD/C were limited to a
handful of case reports (74,76–79). In 2007, Bomma
et al. (75) conﬁrmed the feasibility and diagnostic
potential of MDCT in a series of 31 ARVD/C referrals,
of whom 17 met diagnostic TFC. In addition, Nakajima
et al. (80) showed that electrocardiogram-gated
MDCT differentiated between ARVD/C and other
causes of ventricular arrhythmia. Komatsu et al. (81)
recently studied 16 patients with ARVD/C who un-
derwent pre-procedural MDCT before epicardial
ablation. The authors report good concordance
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609between epicardial low voltage and fat on MDCT,
with ablation targets clustering in the border of the
fat region. This study reveals the potential of MDCT
in the localization of an arrhythmic substrate and
potential therapeutic applications in ARVD/C.
CT PROTOCOL FOR ARVD/C. Many patients with
ARVD/C are young, and thus efforts must be made to
reduce radiation dose otherwise associated with
cine CT. The latest second- and third-generation CT
scanners have enhanced reconstruction algorithms
that allow reduced radiation exposure. In addition,
the temporal resolution of scanners has dramatically
improved over the past 5 to 10 years.
Patients undergoing cine CT likely require control
of heart rate using antiarrhythmic medication. Mul-
tiple ectopic ventricular beats will result in high
radiation dose and prolonged breath-holds. The
optimum CT protocol will heavily depend on the
technological sophistication of the CT equipment.
However, several general conclusions can be made:
1. Calcium scoring and coronary artery imaging
are generally not needed for ARVD/C patients.
Reduction of these 2 components of the CT ex-
amination may reduce radiation dose by 3 to
10 mSv or more depending on the scanner
generation.
2. Opaciﬁcation of both the RV and the LV with
iodinated contrast is necessary for optimal visual-
ization of wall motion abnormalities. Thus, modi-
ﬁcation of the typical CT angiogram contrast
injection protocol is needed (where contrast opa-
ciﬁcation of only the LV is usually desirable).
3. Temporal resolution of the CT image is worse
than using CMR unless a segmented cardiac
acquisition is used; segmented acquisitions (mul-
tiple heartbeats) in turn result in substantially
increased radiation dose to the patient. Although
a 320-slice CT scanner can produce an approxi-
mately 50 ms cine CT image in 3 heartbeats,
an older generation 64-slice scanner may show
markedly lower temporal resolution (100 to
150 ms) when used in a comparable multi-heartbeat
mode.
4. Reconstruction oversampling of the time domain
(cine) images is important to provide high-quality
cine images. By using older 64-slice technology,
we previously reconstructed 10 images during
the cardiac cycle, or 1 image per 100 ms resolution
(at 60 beats/min heart rate). On the other hand, 50
ms cine imaging is now available; 40 cine images
per heart cycle can be reconstructed for optimal
depiction of the cardiac cycle. Given the large
number of CT images generated, reconstructedslice thickness of 4 to 5 mm is sufﬁcient for
visualization and quantiﬁcation of ventricular
function.
CURRENT USE OF CT IN ARVD/C. Cardiac CT is not
included in the diagnostic TFC and thus usually not
part of the initial screening of patients with suspected
ARVD/C. However, a possible use of CT lies in the
evaluation of claustrophobic patients, assessment
of subjects with frequent ventricular extrasystoles
leading to severe arrhythmia artifacts on CMR,
and serial evaluation of ICD carriers. Although
CMR-compatible ICDs have become available, device
artifacts degrade CMR quality, rendering the exami-
nation unusable. In addition, CT may be valuable for
procedural planning of subjects undergoing ablation
procedures (81). The latest third-generation MDCT
scanners have the potential for 1 to 2 mSv cine CT
images at acceptable temporal resolution (50 to
100 msV). We believe this modality will be increas-
ingly used in the future for evaluation of patients
with ARVD/C.
CONCLUSIONS
Noninvasive imaging plays an important role in
ARVD/C evaluation. For diagnostic purposes, the 2010
TFC prescribe the use of TTE or CMR. Because of its
low cost and widespread availability, conventional
TTE is often used as a ﬁrst-line imaging technique
for ARVD/C. Although not included in the diagnostic
criteria, previous studies have shown that echocar-
diographic deformation imaging using TDI or speckle
tracking is a promising tool to diagnose early, subtle
RV changes. CMR has 3D multiplane capability and
high spatial resolution. CMR is uniquely suited for
ARVD/C evaluation because it allows for both mor-
phological and functional characterization, as well as
evaluation of ﬁbrofatty replacement, the pathologic
hallmark of ARVD/C. Although not part of the diag-
nostic TFC, CT has excellent spatial resolution, reli-
able image quality, and fast acquisition at low costs.
With the decreasing radiation dose and increasing
familiarity of physicians with CT ﬁndings in ARVD/C,
CT may play an important role both in the diagnosis
and the follow-up of patients with ARVD/C. Studies
comparing different imaging techniques would fur-
ther our knowledge on the utility of each technique
for ARVD/C evaluation.
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